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Abstract
Primary graft dysfunction is the main cause of early mortality after heart transplantation 
(HT). Preventive strategies to avoid primary graft dysfunction (PGD) have been focused 
on better donor choice and maintenance, heart preservation methods in long-distance 
retrievals with prolonged ischemia time, and better myocardial protection during 
implantation, among others. Hemodynamic deterioration, caused by cardiogenic shock 
due to pump failure unresponsive to inotropes, has a catastrophic progression if not cor-
rected in time. Severe PGD without response to inotropes and heart rhythm control in the 
absence of cardiac tamponade should be treated promptly with mechanical circulatory 
support. Extracorporeal life support (ECLS) should be installed early, before the occur-
rence of multiorgan dysfunction or prior to cardiac arrest, as highlighted in the literature. 
The aim of this chapter is to discuss the use of mechanical circulatory support (MCS) and 
its impact on the success to survival for patients with PGD.
Keywords: extracorporeal membrane oxygenation, mechanical circulatory support, 
primary graft dysfunction, orthotopic heart transplantation, heart failure, heart-assist 
devices
1. Introduction
Heart transplantation (HT) remains the preferred treatment for end-stage heart disease that 
currently affects 5.1 million people in the United States, with an estimated growth of 25% by 
2030 [1]. More than 4000 patients undergo HT annually worldwide for this condition [2, 3], 
with an improved survival rate in the last two decades. Through the years, the advent of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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multiple platforms of mechanical circulatory support (MCS) as an arm of transplantation has 
made it possible to rescue patients that were too sick to be treated without the help of devices.
Despite surgical advances and improved long-term survival, heart transplant patients are still 
at significant risk to develop early graft dysfunction (EGD), leading to significant periopera-
tive morbidity and mortality [2, 4, 5]. Notwithstanding the better results of HT, mortality from 
EGD varies among centers and over the years. In addition, the different set of criteria jeopar-
dize comparison for incidence and mortality.
There are two basic entities that compose of EGD: primary graft dysfunction (PGD) and sec-
ondary graft dysfunction (SGD). The latter is based on pathology-proven rejection, clear sur-
gical complications, or hemodynamic parameters. A postoperative transpulmonary gradient 
greater than 15 mmHg, associated with low cardiac output, was considered as graft dysfunc-
tion secondary to pulmonary hypertension classified as SGD. The aim of this chapter is to 
discuss exclusively cardiogenic shock due to PGD and its management. Secondary graft dys-
function is not the scopes of this chapter.
2. Primary graft dysfunction
2.1. Definitions and classification
Primary graft dysfunction is reported as dysfunction affecting the right ventricle (RV), left ven-
tricle (LV), or both, according to echocardiographic findings. Primary graft dysfunction (PGD) 
is common and ranges from 2.3 to 28.2% depending on the definition [6–10].
The diagnosis of PDG should be considered if any dysfunction is observed at the end of 
cardiopulmonary bypass, restricted to the first 24 h after surgery and based on echocardio-
graphic and/or hemodynamic criteria, as summarized in Table 1.
Severe PGD is defined as the need for MCS—other than an intra-aortic balloon pump—
to maintain an adequate organ perfusion following HT and is the leading cause of early 
mortality after transplantation [5]. Hemodynamic deterioration caused by cardiogenic 
shock due to pump failure unresponsive to inotropes has a catastrophic progression if not 
addressed in time. For this reason, heart transplant patients should be routinely moni-
tored by a pulmonary artery catheter. It provides continuous information about cardiac 
output and other real-time hemodynamics parameters required for therapeutic decision-
making, in combination with other clinical variables, such as tissue perfusion. In a PGD 
after HT, the amount of inotropes and vasopressors—vasotropic score—the patient is on 
and micro- and macro-hemodynamics help to decide whether to rely on medical manage-
ment or choose MCS.
Intraoperative transesophageal echocardiography (TEE) is recommended routinely upon the 
discontinuation of cardiopulmonary bypass. It provides useful information about ventricular 
dimensions and function, blood volume, residual surgical defects, and helps to de-air cavities. 
If the diagnosis of postoperative shock is challenging, both operating room (OR) and bedside 
echocardiography are informative and should be performed whenever cardiac dysfunction 
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and hemodynamic parameters indicate cardiogenic shock. Figure 1 shows a suggested algo-
rithm to rule out PGD post-heart transplantation.
In a recent consensus on April 23, 2013, during the annual meeting of the International Society 
of Heart and Lung Transplantation (ISHLT) [5], PGD was defined as any graft dysfunction 
that occurs up to 24 h after transplantation. This agreement formulates guidelines to better 
define the diagnosis and management of patients with primary graft dysfunction (PGD) in 
heart transplantation. Before the conference, an online survey was used to obtain contempo-
rary thoughts on diagnosis and management of PGD patients from transplant centers. A total 
of 47 transplant centers responded and the results are summarized in Table 1. Epidemiology 
factors were set as the baseline. Parameters such as the requirement of inotropic support, 
left ventricular ejection fraction (LVEF), and requirement of cardiac mechanical support were 
put as possible criteria for PGD. The purpose of this consensus was to initiate a standardiza-
tion of the study of PGD and serve as a guide for the heart transplant community  regarding 
 diagnosis, management, and risk stratification of post-transplanted PGD, thus permitting 
uniform comparisons among centers and studies.
Table 1. Classification of primary graft dysfunction after heart transplantation.
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The conference had 71 participants— including cardiologists, cardiac surgeons, pathologists, and 
immunologists—representing 42 heart transplant centers from North America, Australia, Europe, 
and Asia, that had published on PGD or had vast clinical experience in heart transplantation.
Additionally, the moment to start support is not well stablished. A high inotropic score seems 
to be related with worst prognosis. Beside high inotropic score, the need of vasotropic agents 
to sustain hemodynamics plays an important rule in chose for ECLS in PGD. It is important to 
acknowledge that a vasoactive-inotropic score (Figure 2 ), rather only the inotropic score, may 
determine better the prognosis and initiation of support. In Cardiogenic shock patients, a high 
vasoactive-inotropic score during the first 48 hours was related with increased in-hospital 
mortality [11, 12].
Figure 1. Ruling out secondary graft dysfunction in heart transplantation.
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2.2. Etiology and pathogeneses
The etiology of PGD is likely to be multifactorial. Donor, procedure and recipient causes are 
involved. Brain death and its sequelae in the donor, hypothermic ischemia during transport, 
warm ischemia during implant surgery, and reperfusion injury after the release of the aortic 
cross-clamp in the recipient can negatively affect the donor’s heart. In addition, systemic fac-
tors in the recipient may create a “hostile” environment that further compromises its function 
after reperfusion and contributes to the development of PGD.
It is important to say that PDG is a phenomenon not correlated with hyperacute rejection. The 
results of the International Society of Heart and Lung Transplantation (ISHLT) autopsy sur-
vey pre-consensus showed that less than 4% of biopsies had some kind of antibody-mediated 
rejection and 7% had evidence of cellular rejection [5].
2.2.1. Donor aspects
Donor’s brain death is associated with a series of events that result in impaired myocardial 
contractility and sensitize the heart to ischemia–reperfusion injury [13]. These events include 
an intense release of endogenous norepinephrine that results in mitochondrial and cytosolic 
calcium overload that may activate autophagy, apoptosis, or necrosis. Calcium overload of 
the contractile proteins leads to contracture and is associated with a characteristic histologic 
appearance known as “contraction band necrosis.” Administration of exogenous catechol-
amines during donor resuscitation may contribute to desensitization of myocardial β-receptor 
signaling after brain death. Many other donor-related aspects leading to PGD are described, 
including ischemic preconditioning insults related to older donors [14].
Most donor hearts are transported and stored in a cold preservation solution and that slows 
but does not effectively arrest cellular metabolism. Consequently, a progressive ischemic 
injury is an inevitable consequence of prolonged static storage.
Furthermore, the reperfusion of the heart with oxygenated blood leads to further calcium 
overload and an initial burst of oxygen-derived free radicals that bind to and disrupt the 
function of multiple cellular enzymes. The combination of Ca+ overload and high oxidant 
stress in an energy-depleted cardiac myocyte activates the formation of the mitochondrial 
permeability transition pore (MPTP)—a non-specific channel that forms in the mitochondrial 
membrane allowing pro-apoptotic factors, such as cytochrome C, to be released into the cell 
cytoplasm [15]. Water that enters by the MPTP causes mitochondrial swelling and may lead 
to membrane rupture, triggering necrotic cell death. Currently, there is an increasing interest 
Figure 2. Vasoactive-ionotrophic criteria: The need of a vasoactive score higher than 85 seems to determine worst 
prognosis in cardiogenic shock patients [11].
Mechanical Circulatory Support (MCS) for Primary Graft Dysfunction (PGD)
http://dx.doi.org/10.5772/intechopen.76697
93
in ex-vivo perfusion of the donor’s heart in order to preserve the organ, minimize the above-
mentioned negative impact of preimplantation ischemia, and increase availability [16].
2.2.2. Recipient aspects
Vasoplegia has a catastrophic result on any heart surgery, particularly in heart transplant, in 
which it seems to affect the donor’s heart impairing its ability to adapt to this hostile envi-
ronment. Many aspects of the receptor are involved in the genesis of this phenomenon. Risk 
factors include mechanical circulatory support before transplantation, prolonged cross-clamp 
time, and significant transfusion requirements. The activation of systemic inflammatory 
response in the recipient results in a vasodilated systemic circulation that is refractory to con-
ventional vasopressor support that seems to lead to PGD. It probably involves the concerted 
action of multiple pro-inflammatory cytokines leading to upregulation of inducible nitric 
oxide synthase or indoleamine dioxygenase, with overproduction of nitric oxide or other 
endogenous vasodilators.
2.3. Risk factors
Transplanted hearts are at risk of ischemia/reperfusion injury, damage from proinflamma-
tory cytokines, and beats on decreased donor cortisol and thyroid hormone levels [17–21]. 
Recipient-related factors include age, increased pulmonary vascular resistance (PVR), and 
recipient inflammatory cytokines, which can worsen vasoplegia, as well as oxidative stress 
in the transplanted heart [22–30]. In addition, transplant recipient dependence on pre-trans-
plantation inotropic support and mechanical ventilation has been associated with increased 
incidence of PGD [24, 31–34].
In a single-center study, Segovia et al. [26] developed a predictive model for the development 
of PGD. The risk factors were included in the model and used to calculate a predictive score 
are recipient age ≥ 60 years, recipient diabetes mellitus, recipient inotrope dependence, right 
atrial pressure ≥ 10 mm Hg, donor age ≥ 30 years, and ischemic time ≥ 4 h (RADIAL score) 
[26]. This model was later validated in a separate cohort of HT performed at programs in 
Spain between 2006 and 2010 [35]. In the latter study, PGD occurred with an incidence of 
22%. Isolated RV dysfunction was present in 45% of patients with PGD, whereas isolated LV 
PGD occurred in 8% of patients and combined biventricular PGD in 47%. The RADIAL score 
was higher in patients with PGD and stratified patients into groups with incremental PGD 
incidence [35].
Nicoara et al. [36] conducted a single-center retrospective cohort study to evaluate the inci-
dence, trends, and independently associated risk factors for PGD after HT. In addition, they 
explored the performance of the RADIAL score variables in this study population. Of the 317 
patients who underwent HT over the study period and met inclusion criteria, 99 (31.23%) 
developed PGD defined according to the ISHLT consensus statement [5]. Isolated PGD-LV 
occurred in 60 patients (18.9%), 22 patients (7%) had biventricular PGD and 17 patients (5.3%) 
had isolated PGD-RV. Risk factors independently associated with the type of PGD included 
ischemia time, recipient African American race, and recipient pre-transplantation treatment 
with amiodarone [36].
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Several studies previously identified a variety of donor, recipient, and procedural risk fac-
tors associated with PGD, with a high variability of results giving different definitions, use 
of single-center or multi-center databases, and different time periods analyzed [37, 38–41]. 
Most consistently among these are donor age [22], donor high dose of inotropic support [24], 
cause of brain death [24], recipient age [24, 36], recipient inotropic support [26], mechanical 
support [22, 24], ischemia time [24, 36], and donor-recipient weight mismatches [32]. Several 
studies [36–37, 42] identified ischemia time as an independent risk factor associated with PGD 
development, with each additional hour of ischemia time almost doubling the risk of PGD.
2.3.1. Amiodarone use
Recipient treatment with amiodarone pre-transplantation has been controversially discussed, 
with divergent results regarding early graft failure, morbidity, and mortality after heart trans-
plantation [43–46]. Nicoara et al. [36] found that recipient pre-transplantation’s use of amio-
darone was an independent factor that increases the risk of PGD development, by 67%. The 
30-s official adult heart transplantation report from the registry of ISHLT did not find amioda-
rone independently associated with early graft failure. However, we had a higher incidence of 
early graft failure and in-hospital graft dysfunction among patients treated with amiodarone, 
suggesting that it may play a role in early post-transplantation outcomes or may be associ-
ated with an unmeasured indicator an ill patient population [3]. A recent retrospective cohort 
analysis of adult HT recipients from the ISHLT registry found that amiodarone use before HT 
has increased over time and is associated with increased 1-year mortality [46]. The long half 
life of amiodarone combined with its pharmacological effects—negative chronotropic and 
inotropic, calcium channel blockage, and α- and β-receptor blockade—may be responsible for 
its effects or an unidentified interaction with oxidative stress leading to worsening ischemia–
reperfusion injury, but this is speculative [46].
2.3.2. Congenital heart disease
Over the last decade, the advances in the medical and surgical management of patients with 
congenital heart disease (CHD) have led to an improvement in their life expectancy with 
85% of children surviving till adulthood [47]. However, some patients will develop late 
myocardial dysfunction resulting in heart failure with 10–20% of them requiring heart trans-
plantation [48, 49]. Adults with congenital heart diseases recipients (ACHDR) pose unique 
challenges due to complex anatomy, multiple prior procedures, preformed human leucocyte 
antigen (HLA) antibodies, pulmonary hypertension, and malnutrition [50]. Because of these 
complexities, ACHDR has a higher operative [51, 52] and a 1-year mortality [2, 53].
In ACHDR, graft dysfunction was seen more commonly when compared to non-cardiac 
recipients (NCR) (9.9% vs. 7.4%, p < 0.01).
United Network for Organ Sharing (UNOS) database reports three categories of graft dys-
function: primary non-function, that is, primary graft dysfunction (PGD), acute rejection, and 
chronic rejection. PGD was significantly higher in ACHDR compared to NCR (4.3% vs. 2.6%, 
p < 0.01); however, there was no difference in acute and chronic rejection rates [49]. PGD con-
tinues to be a significant cause of morbidity in the most recent era [54].
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Graft and cardiovascular dysfunction in ACHDR were the top two causes of early mortality 
and most likely related to the presence of elevated PVR, allosensitization, and longer donor 
organ ischemic times [30, 55–59]. The ACHDR were more likely to have longer-than-4-h 
ischemic times, peak panel-reactive antibody (PRA) class II >10%, and were found to have 
a higher rate of graft failure due to primary graft dysfunction. Thompson et al. showed that 
early graft survival was directly related to the number of HLA-DR (class-II) mismatches [59]. 
Graft dysfunction and postoperative bleeding are more likely to cause death in ACHDR com-
pared to non-cardiac recipients (NCR) [49, 53, 60]. Because of graft dysfunction and young 
age, the re-transplant rate is higher among ACHDR compared to NCR [49, 55]. Improvement 
in the graft dysfunction rate in recent times can be attributed to better medical management 
of mild PGD with the use of levosimendan, nitric oxide, and phosphodiesterase inhibitors. 
The short-term survival for ACHDR is poorer as compared to NCR, and primary graft dys-
function remains a significant issue affecting short-term survival in ACHDR. The fact that 
the ACHDR who survives the first post-transplant year have better long-term survival than 
NCR indicates that perioperative mortality and morbidity is most likely the Achilles heel for 
cardiac transplantation in ACHDR [54]. Management of severe PGD with early intervention 
and short-term mechanical support appears to have improved survival [5].
3. Mechanical circulatory support
MCS may be provided by VA-ECMO or the implantation of a temporary paracorporeal ven-
tricular assistance device (VAD) and the choice depends on the knowledge about devices 
and shelf-available items. There’s no manual or evidence-based decision-making protocol 
to choose one or another. Nevertheless, ECLS management may determinate success to dis-
charge of patients experiencing PGD.
Advances in durable MCSs (LVADs) made its use reliable in patients with heart failure as a 
bridge to heart transplant, as well as postoperative support with ECLS in PGD HT to allow 
organ recovery. Although an LVAD is usually the choice for consistent outcomes in patients 
supported while waiting for a heart transplant, ECLS may be used in patients in whom LVADs, 
BiVADs, or TAH (total artificial hearts) are not reliable or available. It includes patients who 
are likely to receive a heart transplant within a short time period after listing.
ECLS use in heart transplant PGD continues to be the first line of support with some recent 
evidence of improved outcomes. There is some evidence on the use of short-term VAD 
but with limited results in a real-world setting [61]. Although further studies are neces-
sary to understand the optimal role of ECLS in heart transplantation the objective of this 
chapter is to discuss its role in PGD, that accounts for 40–50% early mortality after heart 
transplantation according to studies using the International Society of Heart and Lung 
Transplantation (ISHLT) registry [5]. Mechanical circulatory support may be provided by 
VA-ECMO or implantation of a temporary VAD. In a recent analysis of 54 patients sup-
ported on ECMO for PGD in a large French center, 36 patients (67%) were weaned from 
the assisting device and 27 of the patients supported with ECMO (50%) were discharged 
from the hospital [62].
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The overall conditional survival was 73% at 1 year and 66% at 5 years. The authors concluded 
that ECMO support is a reliable therapeutic option for severe, early graft failure after cardiac 
transplantation. Furthermore, patients treated with ECMO had the same 1-year conditional 
survival as patients who did not suffer from PGD. In this study, the authors found no differ-
ence in weaning when comparing peripheral ECMO and central ECMO (50%) but a higher 
rate of vascular complications (18%) in patients supported on peripheral ECMO.
The device of choice and timing of insertion varies among institutions, and the use of mechani-
cal circulatory support tends to be more liberal for early support in high-volume centers with a 
potentially positive effect on graft recovery [63]. Although ECMO has been traditionally favored 
due to the ease installation, and the ability to provide oxygenation following a prolonged cardio-
pulmonary bypass, its use is associated with increased risk of bleeding, insufficient LV unload-
ing, and the chance of intracardiac thrombosis in patients with minimal sistolic function [64, 65].
Takeda and colleagues from Columbia University performed an analysis of patients requiring 
mechanical support for PGD following heart transplant [66]. Of the 597 patients who received 
a heart transplant during the study period, severe PGD developed in 44 (7.4%). Within 24 h 
of transplant, 17 of these patients received support via a continuous-flow external VAD, and 
27 received VA-ECMO support. The patients who received a VAD were more likely to have a 
longer support time, major bleeding requiring chest re-exploration, and renal failure requir-
ing renal replacement therapy after surgery. In-hospital mortality was 41% for VAD patients 
and 19% for VA-ECMO patients. A total of 10 patients (59%) were weaned from VAD support, 
and 24 patients (89%) were removed from VA-ECMO support after adequate graft function 
recovery. The 3-year post-transplant survival was 41% in the VAD group and 66% in the 
VA-ECMO group, leading to the conclusion that for severe PGD, support with VA-ECMO 
appears to result in better clinical outcomes than VAD support. ECMO in patients with PGD 
or allograft failure due to other causes seems to be associated with better outcomes than 
ECMO support for other reasons. Tran and colleagues [67], from UCLA, demonstrated that 
patients requiring ECMO for graft failure after heart transplant had lower mortality (51.6%) 
when compared with patients who needed ECMO for other etiologies (69.1%).
ECLS/ECMO seems to be the best way to support PGD patients in almost all scenarios for 
many reasons. It can provide safe maximum flow and pulmonary support with different can-
nulation strategies—percutaneously, hybrid, or by central access. It is rapidly installed, and 
cost of disposable equipment is relatively inexpensive compared with other devices. In basic 
settings, veno-arterial (VA) ECMO is considered the main strategy. Central access is prefer-
able due to fast installation, direct evaluation of the heart decompression, and easiest way to 
install a left-side drainage cannula in the left atrium or left ventricle if it remains distended.
A total of 16% of our PGD patients had a left cannula installed as a venting strategy to guar-
antee LV resting. Our preference is to use central VA ECMO. Patients may be extubated as 
any other heart surgery postoperatively after recovering from anesthesia. Cannulas may be 
positioned inferiorly through the thoracic wall and the chest fully closed to facilitate mobility 
and ambulation. Extubation may be done even if only the skin is closed—not sutured ster-
num. In this case, the care team has to ensure a sealed bandage around the cannulas to avoid 
pneumothorax formation.
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Full support is sufficient when hemodynamic variables and microperfusion are normalized—
VA ECMO usually provides normal oxymetric parameters if the patient is well supported. 
MAP goal usually is around 70, CVP < 15, SVO2 > 60%, serum lactate <2.0 mmol/L, and O2 saturation > 95%. Since the pulmonary flow is shunted throw the ECLS system, pulmonary 
artery pressures are expected to be very low, and most of the times cardiac index cannot be 
measured. Pulsatile waveforms are almost invisible or show a very low pulse pressure gradi-
ent (less than 20 mm Hg).
Usually, in the range of 3–7 days, it is possible to see some degree of heart recovery. Pulse 
pressure may rise above 20 mmHg, CI may be measurable through PAC, pulmonary pres-
sures may rise, and the patient may be hemodynamically stable with a lower flow on ECLS 
system. At this point, the weaning protocol should require an echocardiographic evaluation to 
reassess biventricular function. In adults, patients showing aortic time-velocity integral (VTI) 
≥10 cm, left ventricular ejection fraction (LVEF) >20–25%, and lateral mitral annulus peak 
systolic velocity (TDSa) ≥6 cm/s at minimal ECMO flow were all successfully weaned [68].
Although ECMO may provide adequate support, it has limitations such as insufficient LV 
unloading, limited time of support, and risks of thromboembolic and vascular complications. 
High pressures in left chambers may not be easily documented, and the patient may run with 
hemodynamic instability. Non-treatable low flow related to sequestration of stroke volume 
in the lungs, secondary of left chambers distention, and inability of the heart to decompress 
from ECMO post-load augmentation may be seen. A documented left-side heart high pres-
sure requires an immediately strategy to unload left chambers and re-establish the desired 
flow. A drainage cannula in left atrium or ventricle that allows a fast connection on the ECMO 
circuit permits good drainage and is a feasible choice. It is important to note that, in this case, 
optimum flow will be achieved after a left-side drainage cannula insertion.
In case of recovery of the left ventricle’s ability to unload, the left cannula may be removed before 
starting the weaning protocol or just reducing the ECMO to allow filing up the ventricle and con-
sidering weaning. Intra-aortic balloon pump has been documented, but in a different scenario 
setting, as a way to reducing systemic vascular resistance, helping to prevent LV distention, dur-
ing the VA ECMO run [69]. More recently, in the largest US-based retrospective study, the addi-
tion of Impella to VA-ECMO for patients with refractory cardiogenic shock was associated with 
lower all-cause 30-day mortality, lower inotrope use, and comparable safety profiles as com-
pared with VA-ECMO alone. This study reinforces the importance of LV decompression as an 
important factor to improve outcomes during VA ECMO in severe ventricular dysfunction [70].
If recovery is not noted on PGD, other strategies should be considered and palliative care may 
be an option. Although we were able to prolong ECMO support in an infant up to 44 days 
until recovery, a biventricular support including a durable VAD or a total artificial heart may 
be an option in selected patients. Since there is lack of evidence to support use of those alter-
natives on PGD, the selection of a device should be made according to the patient’s clinical 
condition and the center’s experience.
3.1. Personal experience
Between January 2007 and December 2013, a total of 71 heart transplantations were performed 
in patients with advanced heart failure and 11 (15.5%) of these patients presented PGD [71]. 
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All patients had advanced heart failure and 2 (18.2%) patients were in a priority state before 
the transplantation. As for the etiology of the cardiomyopathy, 5 (45.4%) were due to Chagas 
disease, 3 idiopathic dilated cardiomyopathy, 1 from secondary to valvular cardiomyopathy, 
1 had restrictive cardiomyopathy, and 1 was associated with peripartum cardiomyopathy. 
None of the patients had PRAc—preformed antibodies calculated panel—above 10%.
In our experience, the causes of PGD were not associated with severe rejection, as documented 
by routine endomyocardial biopsy in the first week, with only one patient presenting cellular 
rejection greater than 2R. Donors were predominantly male (n = 7; 63.6%) and had an aver-
age age of 26.6 ± 12.3 years (ranging from 15 to 48 years). The causes of death among donors 
included head trauma in 7 cases (63.6%), hemorrhagic stroke in 3 (27.3%), and cerebral tumor 
in 1. A total of 7 cases (63.6%) received continuous infusion of norepinephrine >0.1 mcg/kg/
min at the time of the retrieval. Retrievals took place in the same hospital of the implantation 
in 6 (54.5%) cases and at a distant center in the 5 remaining cases. The average ischemia time 
was 151 ± 82 min (ranging from 73 to 270 min), with 82.8 ± 14.2 min in the local retrievals and 
233 ± 35.4 min in distant retrievals (p < 0.0001). The cold ischemia “limit” of 4 h was exceeded 
in 2 (18.2%) patients.
In this group of patients, the use of ECMO met the desired goals, promoting cardiac recovery 
in most cases, with acceptable complication rates, considering the severity of the clinical con-
dition of patients [71]. We were successful in removing the ECMO, with cardiac recovery in 
81.8% of the patients after an average of 76 h. The main postoperative problems that we found 
were acute renal failure, stroke, and requirement for surgical revision of hemostasis. The first 
is a frequent complication [72] and is secondary to multiple insulting factors—shock, neph-
rotoxic drugs, and systemic venous congestion—and pre-transplant cardiorenal syndrome. 
Renal function recovered in all patients after a few sessions of hemodialysis, as described by 
Listijono et al. [73]. The last two are complications related to the requirement of anticoagula-
tion during ECMO, which is difficult to control. Complicating factors are recent heart surgery, 
the presence of shock with concomitant hepatic dysfunction, and, eventually, disseminated 
intravascular coagulation. Excessive use of blood products complicates immunological sen-
sitization, systemic congestion—including liver congestion, which increases bleeding—and 
pulmonary hypertension. The use of heparin-coated circuits, antifibrinolytics, careful surgical 
technique, maintenance of hemodynamic stability with systemic venous decompression, and 
synthetic derivatives of coagulation factors are important to minimize these complications. 
Although patients who developed stroke showed increased hospital mortality, those who 
survived had full recovery of motor activity without limitation in their quality of life.
4. Conclusion(s)
The aim of circulatory assistance in PGD is always cardiac recovery. Thus, the characteris-
tics of the ideal device must comply with the following requirements: ability to be quickly 
installed, allowing the rapid re-establishment of cardiac output in order to maintain ade-
quate tissue perfusion and reverse multiorgan dysfunction, reducing ventricular filling pres-
sures, promoting myocardial protection with increased coronary flow, and having a low 
 complication rate.
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Heart decompression is important for a successful recovery since intracavitary hypertension 
curtails subendocardial coronary perfusion, especially in those patients who had no electrical 
activity or lacked sufficient contractile activity for adequate LV decompression.
Regardless of showing complete recovery, patients with PGD have a higher mortality when 
multiple organs were involved. Hence, there is need for strengthened intensive care in this 
population, systematically focused on the management of organs and systems and on the 
prevention of sepsis.
The rapid hemodynamic deterioration due to PGD shows that the earlier the implantation 
(operation room), the best are the outcomes for weaning and survival. Patients in whom 
ECMO was initiated due to cardiac arrest had a poor outcome, and the appropriate timing 
was certainly neglected.
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